Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for AZN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
March 31, 2026 7.675B
December 31, 2025 5.741B
September 30, 2025 8.182B
June 30, 2025 7.108B
March 31, 2025 5.395B
December 31, 2024 5.654B
September 30, 2024 4.93B
June 30, 2024 7.076B
March 31, 2024 8.021B
December 31, 2023 5.962B
September 30, 2023 5.115B
June 30, 2023 5.812B
March 31, 2023 6.462B
December 31, 2022 6.405B
September 30, 2022 4.898B
June 30, 2022 4.887B
March 31, 2022 5.823B
December 31, 2021 6.398B
September 30, 2021 7.149B
June 30, 2021 15.63B
March 31, 2021 7.765B
December 31, 2020 7.992B
September 30, 2020 8.446B
June 30, 2020 6.115B
March 31, 2020 4.165B
Date Value
December 31, 2019 6.218B
September 30, 2019 4.78B
June 30, 2019 6.247B
March 31, 2019 4.958B
December 31, 2018 5.68B
September 30, 2018 4.262B
June 30, 2018 3.81B
March 31, 2018 3.871B
December 31, 2017 4.582B
September 30, 2017 5.211B
June 30, 2017 6.263B
March 31, 2017 3.672B
December 31, 2016 5.929B
September 30, 2016 4.025B
June 30, 2016 4.651B
March 31, 2016 4.107B
December 31, 2015 6.855B
September 30, 2015 4.607B
June 30, 2015 4.549B
March 31, 2015 3.722B
December 31, 2014 7.176B
September 30, 2014 5.957B
June 30, 2014 5.778B
March 31, 2014 5.164B
December 31, 2013 10.05B

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
GSK Plc 4.122B
Johnson & Johnson 20.76B
Eli Lilly & Co. 8.95B
Merck & Co., Inc. 7.182B
Novo Nordisk A/S 6.880B